Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment
Year: 2016
Type: article
Study design: Clinical Trial
Abstract: Anti-VEGF antibody bevacizumab has prolonged progression-free survival in several cancer types, however acquired resistance is common. Adaption has been observed pre-clinically, but no human study has shown timing and genes involved, enabling formulation of new clinical paradigms. In a window-of-opportunity study in 35 ductal breast cancer patients for 2weeks prior to neoadjuvant chemotherapy, we monitored bevacizumab response by Dynamic Contrast-Enhanced Magnetic Resonance [DCE-MRI], transcriptomic and pathology. Initial treatment response showed significant overall decrease in DCE-MRI median K(trans), angiogenic factors such ESM1 and FLT1, and proliferation. However, it also revealed great heterogeneity, spanning from downregulation of blood vessel density and central necrosis to continued growth with new vasculature. Crucially, significantly upregulated pathways leading to resistance included glycolysis and pH adaptation, PI3K-Akt and immune checkpoint signaling, for which inhibitors exist, making a strong case to investigate such combinations. These findings support that anti-angiogenesis trials should incorporate initial enrichment of patients with high K(trans), and a range of targeted therapeutic options to meet potential early resistance pathways. Multi-arm adaptive trials are ongoing using molecular markers for targeted agents, but our results suggest this needs to be further modified by much earlier adaptation when using drugs affecting the tumor microenvironment.
Source: EBioMedicine
Institutions: University of Oxford, Mount Vernon Cancer Centre
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: bevacizumab, anti-angiogenic therapy, acquired drug resistance, breast ductal carcinoma, radiogenomics, DCE-MRI, Ktrans, tumor angiogenesis, glycolysis, pH adaptation, PI3K/Akt signaling, immune checkpoint signaling, ESM1, Flt-1, tumor microenvironment, neoadjuvant chemotherapy, adaptive trial design
Open Access status: gold
Estimated APC paid: $5,780
OpenAlex ID: W2495002122
